Review of a rare but important cardiac dysplasia causing high mortality and morbidity in mostly young patients.
In this presentation, the epidemiology, pathophysiology, diagnosis and treatment of said disease is examines.
Review of a rare but important cardiac dysplasia causing high mortality and morbidity in mostly young patients.
In this presentation, the epidemiology, pathophysiology, diagnosis and treatment of said disease is examines.
A lecture on the echocardiographic evaluation of hypertrophic cardiomyopathy. Starts with an overview of the topic then a systematic approach to diagnosis and then a differential diagnosis followed by take-home messages and conclusion.
Speckle tracking echocardiography (STE) is an echocardiographic imaging technique that analyzes the motion of tissues in the heart by using the naturally occurring speckle pattern in the myocardium or blood when imaged by ultrasound.
A lecture on the echocardiographic evaluation of hypertrophic cardiomyopathy. Starts with an overview of the topic then a systematic approach to diagnosis and then a differential diagnosis followed by take-home messages and conclusion.
Speckle tracking echocardiography (STE) is an echocardiographic imaging technique that analyzes the motion of tissues in the heart by using the naturally occurring speckle pattern in the myocardium or blood when imaged by ultrasound.
ARVD is one of important coardiomyopathy in our clinical practice,early diagnosis, risk stratification and early diagnosis of CHF, management of VT will make big difference in patient life
The so Called Brugada Syndrome The True HistoryBortolo Martini
The syndrome of sudden Death, right bundle branch block and ST elevation was firstly described by A.Nava and B. Martini in 1988-1989, and only five years later by the Brugada Brothers. The ECG pattern is due to a conduction disturbance of the RVOT, caused by fibrofatty substitution of that structure.
Acute pulmonary embolism - risk stratification and managementPrithvi Puwar
what is the guideline recommendation and ideal to be done in management of acute pulmonary embolism. the presentation includes risk stratification, recommendation and approach to investigations (guidelines based) and management options with evidence.
Ventricular tachycardia are difficult to understand. it is classified in to two types. 1. VT in structurally normal heart, 2. VT in heart with structural diseases. I have tried to simplify the VT in structurally normal heart, which may be helpful to many students and learners.
PRN Medications; its justified use: by Dr Prithvi PuwarPrithvi Puwar
The presentation is mentioning the details of PRN medications, its common use, the common problems occured by erroneous medications side effects ...A must to know by duty doctor, registrars and nurses. Most of the presentation slides are in interactive way.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
2. ARVD - GENETICS
“ARRYTHMOGENIC RIGHT
VENTRICULAR CARD
IOM
YOPATHY”
• Genetic form of cardiomyopathy
• Familial occurrence of 30% to 50%
• Genetic screening –
- early detection of healthy carriers
- prognostic role in patients
4. ARVD – Molecular mechanism
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• Mutations render desmosomes inappropriately sensitive
to mechanical stresses, resulting in myocyte death
• Signal transduction processes induced by mutant
desmosome proteins can lead to reprogrammed myocyte
cell biology so that these cells adopt a fibrofatty lineage
5. ARVC – Natural History
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• Typically present between the teenage years and the forties
• Prevalence – 1:2000/1:5000
• Male : Female = 1:3
• Natural history characterized by four phases:
- Concealed phase (asymptomatic, but at risk of SCD)
- Overt clinical expression of an electrical system disturbance
- Signs and symptoms of right ventricular failure
- Frank biventricular congestive heart failure
6. History
Common symptoms reported in different series include the
following:
Palpitatio
n (27%-
67%)
Syncope
(26%-
32%)
Sudden
cardiac
death
(10%-
26%)
Atypical
chest
pain
(27%)
Dyspnea
(11%)
It has wide range of presentations, ranging from being
asymptomatic to biventricular failure and/or sudden cardiac
death.
7. Palpitation
• It is the most frequent symptom and is caused by
ventricular arrhythmias.
• Supraventricular arrhythmias, including atrial flutter and
fibrillation, may be seen in about 25% of cases
• Depending on the disease severity, ventricular ectopics
may be isolated or may result in nonsustained/sustained
ventricular tachycardia, ventricular fibrillation
Progressive RV
and LV
dysfunction
• Results In Dyspnea And Leg Swelling.
• In more severe cases with LV involvement,
patients may present with biventricular congestive
heart failure that may mimic DCM
8. SUDDEN
CARDIAC
DEATH
• ARVD accounts for 22% of sudden
cardiac death cases among young
athletes in northern Italy.
• In the United States, hypertrophic
cardiomyopathy was the most
common cause, and ARVD was
reported in only 4% cases
10. The Need To Change The 1994 Criteria
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• 1994 criteria were highly specific, but lacked sensitivity for early and
familial disease
• Additional ECG markers have been proposed in last 15 yrs
• Genetic basis recognized - potential for mutation analysis
• Experience in quantification of imaging criteria of ARVC ↑
• Newer imaging techniques –
- contrast echo, 3D Echo , CMR, SAECG
• Recognition that LV involvement may occur early
11. Framework of New Task Force Criteria
2010
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
The approach
• Global or regional dysfunction and structural alteration
• Tissue characterization of walls
• Repolarization abnormalities
• Depolarization and conduction abnormalities
• Arrhythmias
• Family history
Each category has major and minor criteria
12. Diagnostic Terminology
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• Definite diagnosis (from different categories):
- 2 major or
- 1 major and 2 minor criteria or
- 4 minor
• Borderline (from different categories):
- 1 major and 1 minor or
- 3 minor criteria
• Possible (from different categories):
- 1 major or
- 2 minor criteria
13. CATEGORY -I – “global or regional dysfunction and
structural alteration”
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
Major Criteria Minor Criteria
Echo Regional RV akinesia,
dyskinesia, or aneurysm : + 1
of the following -
Regional RV akinesia
/dyskinesia - + 1 of the following
-
PLAX RVOT ≥32 mm (≥19
mm/m2)
PSAX RVOT ≥36 mm (≥21
mm/m2)
PLAX RVOT ≥29 to <32 mm
(≥16 to <19 mm/m2)
PSAX RVOT ≥32 to <36 mm
(≥18 to <21 mm/m2)
MRI Regional RV akinesia,
dyskinesia or dyssynchrony: +
1 of the following -
RVEDV index: ≥110 mL/m2
(male)
≥100 mL/m2
(female)
RV EF ≤ 40%
RVEDVi : 100 - 110 mL/m2
(male)
90 - 100 mL/m2
(female)
RV EF >40% to ≤45%
RV Angio Regional RV akinesia,
14. Echocardiography in ARVC
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• The most conspicuous findings:
- RV dilation
- Enlargement of the RA
- Isolated dilatation of the RVOT
- Increased reflectivity of the moderator band
- Localized aneurysms, fractional area change, &
akinesis/ dyskinesis of the inferior wall and the RV apex
17. ECHO FEATURES OF ARVC
Excessive trabeculations Hyperreactive
moderator
18. Contrast Echo of the RV
Dilated RV clearly showing enhanced border delineation with a localized aneurysm of the
RVOT.
19. Cardiac MR in ARVC
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• five criteria for diagnosis of ARVC:
(1) High signal intensity (substitution of myocardium by fat)
(2) Ectasia of RVOT
(3) Dyskinetic bulges
(4) Right ventricular dilation
(5) RA enlargement
• Fibrosis is more specific than myocardial fat – detected by
increased delayed enhancement in contrast CMR signal
20. End-diastolic and end-systolic frames of a short-axis cine magnetic
resonance image
showing an area of dyskinesia on free wall of a
dilated RV
21. Axial T1-weighted
black blood spin-
cardiovascular MRI
showing extensive
transmural fatty
replacement of the
RV myocardium
22. 30-80% of (advanced) cases have LV, as well as RV
late GAD enhancement indicating focal fibrosis
24. CATEGORY - II – “Tissue characterization of walls”
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
Endomyocardial
biopsy
Major Criteria Minor Criteria
NEW TFC
Residual myocytes <60%
by morphometric analysis
(or <50% if estimated),
with fibrous replacement
of the RV free wall
myocardium in ≥1 sample,
with or without fatty
replacement of tissue
Residual myocytes 60%–75%
by morphometric analysis (or
50%–65% if estimated),
with fibrous replacement of
the RV free wall myocardium
in ≥1 sample, with or without
fatty replacement of tissue
25. Endomyocardial biopsy - role in ARVD
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• Definitive Dx - histologic demonstration of transmural fibrofatty
replacement of RV myocardium at biopsy/surgery
• Dx based on RV endomyocardial biopsy specimens is limited because
segmental nature of the disease causes false –ve
• Use of electroanatomic voltage mapping to identify pathological areas for
biopsy sampling may improve yield
• RV free wall biopsy has a slight risk of perforation,
• More accessible IVS rarely exhibits histological changes
26. CATEGORY - III – “Repolarization abnormalities”
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
Electrocardiography Major Criteria Minor Criteria
NEW TFC
Inverted T waves in
right precordial leads
(V1, V2, and V3) or
beyond
in individuals >14 yrs
of age
(in the absence of
complete RBBB QRS
≥120 ms)
• Inverted T waves in leads
V1 & in V4, V5, or V6 in
individuals >14 yrs age (in
the absence of complete
RBBB)
• Inverted T waves in leads
V1, V2, V3, and V4 in
individuals >14 years of
age in the presence of
complete RBBB
28. Repolarization Abnormalities
Repolarization abnormalities are early and
sensitive markers of disease expression in
ARVC/D
T-wave inversion in V1, V2, and V3 and beyond
in individuals >14 years of age who are otherwise
healthy is observed in only 4% of healthy women
and 1% of men.
it is reasonably specific in this population and
considered a major diagnostic abnormality in
ARVC/D
Marcus FI. Prevalence of T-wave inversion beyond V1 in young normal individuals and usefulness for the
diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Am J Cardiol. 2005; 95: 1070–1071.
29. CATEGORY -IV – “Depolarization and Conduction
Abnormalities”
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
ECG Major Criteria Minor Criteria
NEW TFC
Epsilon wave in the
right precordial leads
(V1 to V3)
• Late potentials by SAECG in ≥1 of 3
parameters (absence of a QRS ≥110
ms on standard ECG):
- Filtered QRS duration ≥114 ms
- Duration of terminal QRS <40 μV
(low-
amplitude signal duration) ≥38 ms
- Root-mean-square voltage of
terminal
40ms ≤20 μV
• Terminal activation duration of QRS
≥55 ms from the nadir of the S to the
end of QRS, incl. R´, in V1, V2, or V3,
in the absence of complete RBBB
30. during regular sinus rhythm, with an epsilon wave
(arrow) in leads V1–V. The ECG shows a RBBB
pattern.
(Reproducible low-amplitude signals between
end of QRS complex to onset of the T wave)
31. ECG from proband with T-wave inversion in V1 through V4 and prolongation of the terminal
activation duration ≥55 ms measured from the nadir of the S wave to the end of the QRS
complex in V1.
Marcus F I et al. Circulation 2010;121:1533-1541
32. CATEGORY - V – “Arrhythmias”
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
ECG/Holter/
Exercise
Major Criteria Minor Criteria
NEW TFC
Nonsustained or sustained
VT of LBBB morphology
with superior axis
• Nonsustained or sustained VT
of RV outflow configuration,
LBBB morphology with
inferior axis or of unknown
axis
• >500 VES per 24 h (Holter)
35. Exercise and ventricular arrhythmias
• Usually occurrence of symptomatic RV arrhythmias during exercise
• Fibrofat. form arrhythmic substrate induced by adrenergic stimulation
• During exercise testing, 50% to 60% of patients with ARVD show ventricular
arrhythmias: monomorphic LBBB pattern in 96%
• The occurrence of arrhythmic cardiac arrest due to ARVD is significantly increased in
athletes. Particularly in certain regions in Italy, ARVD has been shown to be the most
frequent disease (22%) leading to exercise-induced cardiac death in athletes.
• Diagnosis of ARVD is considered incompatible with competitive sports and/or
moderate-to-high intensity level recreational activities.
36. CATEGORY -VI – Family history
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
Major Criteria Minor Criteria
NEW TFC
• ARVC confirmed in a first-
degree relative
• ARVC confirmed
pathologically at autopsy or
surgery in a first-degree
relative
• Identification of a
pathogenic mutation
categorized as associated
or probably associated with
ARVC in the patient under
evaluation
• History of ARVC in a first-
degree relative in whom it is
not possible or practical to
determine whether the family
member meets current task
force criteria
• Premature sudden death (<35
years of age) due to
suspected ARVC in a first-
degree relative
• ARVC confirmed
pathologically or by current
task force criteria in second-
degree relative
37. Diagnosis of Familial ARVD
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
documentation of one of the following in a family member:
• T-wave inversion V1, V2, and V3 in individuals ≥ 14 years.
• Late potentials by SAECG
• VT of LBBB morphology on ECG, Holter, or during exercise testing or
>200 PVCs in 24 hours
• Either mild global dilatation or reduction in RVEF with normal LV or
mild segmental dilatation of the RV or regional RV hypokinesis.
38. Uhl’s Anomaly VS ARVD/C
The mechanism operating in ARVD/C should be
essentially different from the apoptosis triggered in Uhl’s
anomaly
As in Uhl’s anomaly there is complete loss of RV
myocardium unlike in ARVD/C , where some myocardium
is still present.
Further, there is no fibrofatty replacement of myocytes
observed in Uhl’s anomaly in contrast, which is the main
pathological feature observed in ARVD/C.
39. ARVD/C VS RVOT-VT
RVOT VT ARVD/C
AGE OF ONSET 3RD TO 4TH DECADE 3RD TO 4TH DECADE
SEX FEMALES PREDOM MALES PREDOM
FAMILY HISTORY ----- +++
SCD ------- +++
12 LEAD ECG NORMAL T WAVE
ABNORMALITIES ,
EPSILON WAVES
SAECG NORMAL LATE POTENTIALS
ECHO NORMAL WALL MOTION
ABNORMALITY OR
DILATATION OF RV
ARRHYTHMIAS REPETATIVE
MONOMORPHIC VT
SVT,NSVT,VF
ORIGIN OF
ARRHYTHMIAS
SEPTUM PARIETAL WALL OF RV
41. Recommendations for ICD in ARVD
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
ACC/AHA 2006/2008 guidelines
• Recommend ICD implantation for secondary prevention
in all patients of ARVD with prior sustained VT or
ventricular fibrillation
• ICD implantation is reasonable for the prevention of SCD in
patients with ARVD who have 1 or more risk factors for
SCD
42. RISK STRATIFICATION & ICD USE
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
ACC/AHA 2006/2008 guidelines
• Induction of VT during electrophysiological testing,
• Detection of nonsustained VT on noninvasive monitoring,
• Male gender,
• Severe RV dilation, and extensive RV involvement
• Young age at presentation (less than 5 years),
• LV involvement,
• Prior cardiac arrest, and unexplained syncope serve as markers of risk
• Patients with genotypes of ARVD associated with a high risk for SCD should be
considered for ICD therapy
43. Proposed recommendations for clinical management and
prevention of sudden cardiac death in patients with ARVD
Arrhythmogenic right ventricular dyplasia
An article from the ESC Council for Cardiology Practice
Fernández-Armenta J., Brugada J.
Vol10 N°26 16 Apr 2012
44. Subgroups
Risk
markers
Recommend-
ations
Follow-up
ICD
indication
Definite ARVD
High risk
Aborted SCD
Sustained VT
Unexplained
syncope
Reduce physical
exercise
Avoid competitive
sport
β-blockers
Annually :
ECG,
ECHO vs
CMR
Holter
Exercise
stress
Recommended
Definite ARVD
Moderate risk
Extensive
disease (severe
RV dysfunction,
large LV
involvement)
Nonsustained
VT
SAME SAME Consider
Definite ARVD
Low risk
Remaining
patients with
definite
diagnosis of
ARVD
SAME SAME
Not
recommended
45. ROLE OF CATHETER ABLATION
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• RFA has proven largely palliative due to patchy and progressive nature of
the disease
• RFA currently reserved for patients who experience frequent ventricular
arrhythmias (and ICD shocks) despite optimal therapy with both ICDs
and antiarrhythmic medication
• Role of RFA may continue to increase in the future, as mapping
techniques continue to evolve
46. Combined endocardial and epicardial
substrate guided catheter ablation
Epicardial scar is wider than the endocardial scar
in ARVD
Combined endocardial & epicardial substrate
guided ablation resulted in a very good short-
and mid-term success rate.
The high recurrence rate published in earlier
series may be due to the conventional only-[Combined endocardial and epicardial catheter ablation in arvc. Brugada J.; Circulation: Arrhythmia and EP.
2012;5:111-121]
47. ARVD - CONCLUSIONS
“ARRYTHMOGENIC RIGHT
VENTRICULAR
CARDIOMYOPATHY”
• SCD is the 3rd most common presenting symptom (behind syncope and
palpitations) & the initial symptom in 23% cases
• An increased awareness and prompt recognition of ARVD has considerable
life-saving potential (ICD/transplant)
• Revised TFC is more sensitive than the original TFC,
• A quick diagnosis can be made with only history, ECG & Echo
• Electrical/arrhythmic abnormalities precede morphological changes on
echo/MRI: ECG has highest diag. sensitivity -“this will have practical
significance for the serial assessment of family members at risk of disease
development”
THANK YOU
Editor's Notes
Echo will remain the initial diagnostic approach of choice
Contrast echo - improved endocardial border delineation and enhanced RV opacification
Figure 3. ECG from proband with T-wave inversion in V1 through V4 and prolongation of the terminal activation duration ≥55 ms measured from the nadir of the S wave to the end of the QRS complex in V1. Contributed by M.G.P.J. Cox, Utrecht, the Netherlands.
superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)
inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL)
12 lead ECG from a 25 y.o. man recorded during VT with a LBBB morphology and a
slight-to-moderate right axis, typically originating from the RVOT.
INFERIOR AXIS……MINOR CRITERIA